董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Harwin | 男 | Chair and Director | 37 | 44.88万 | 886.94 | 2023-07-10 |
| Tomas Kiselak | 男 | Director | 37 | 44.00万 | 886.94 | 2023-07-10 |
| Jennifer Fox | 女 | Director | 52 | 46.40万 | 2.78 | 2023-07-10 |
| Peter Harwin | 男 | Chair and Director | 37 | 未披露 | 未持股 | 2023-07-10 |
| Jennifer Fox | 女 | Director | 52 | 未披露 | 未持股 | 2023-07-10 |
| Andrew Gottesdiener | 男 | Director | 32 | 44.88万 | 2.63 | 2023-07-10 |
| William Jones, Jr. | 男 | Director | 60 | 45.54万 | 2.78 | 2023-07-10 |
| Tomas Kiselak | 男 | Director | 37 | 未披露 | 未持股 | 2023-07-10 |
| Nimish Shah | 男 | Director | 45 | 44.45万 | 851.96 | 2023-07-10 |
| Michael Henderson | 男 | Chief Executive Officer and Director | 34 | 129.15万 | 109.53 | 2023-07-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Henderson | 男 | Chief Executive Officer and Director | 34 | 129.15万 | 109.53 | 2023-07-10 |
| Carl Dambkowski | 男 | Chief Medical Officer | 38 | 85.59万 | 22.00 | 2023-07-10 |
| Jane Pritchett Henderson | 女 | Chief Financial Officer | 57 | 85.59万 | 19.60 | 2023-07-10 |
| Rebecca Dabora | -- | Chief Technical Officer | 64 | 未披露 | 未持股 | 2023-07-10 |
董事简历
中英对照 | 中文 | 英文- Peter Harwin
-
Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。
Peter Harwin has served as a member of Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University. - Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。
- Peter Harwin has served as a member of Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University.
- Tomas Kiselak
-
Tomas Kiselak自2024年11月起担任Korsana董事会成员。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是他于2016年4月共同创立的一家医疗投资公司。在加入Fairmount之前，他是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2020年10月起担任Viridian的董事会成员，并自2023年6月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO）的董事，自2023年6月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE），自2020年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。
Tomas Kiselak has served as a member of the Korsana board of directors since November 2024. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, he was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and has been a member of Viridian's board since October 2020, and has served as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since June 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since June 2023, Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2020, and several private companies. Mr. Kiselak previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 until March 2025. He received a B.S. in Neuroscience and Economics from Amherst College. - Tomas Kiselak自2024年11月起担任Korsana董事会成员。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是他于2016年4月共同创立的一家医疗投资公司。在加入Fairmount之前，他是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2020年10月起担任Viridian的董事会成员，并自2023年6月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO）的董事，自2023年6月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE），自2020年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。
- Tomas Kiselak has served as a member of the Korsana board of directors since November 2024. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, he was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and has been a member of Viridian's board since October 2020, and has served as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since June 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since June 2023, Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2020, and several private companies. Mr. Kiselak previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 until March 2025. He received a B.S. in Neuroscience and Economics from Amherst College.
- Jennifer Fox
-
詹妮弗·福克斯，自2022年7月以来一直在董事会和全科医生董事会任职。Fox女士自2020年10月起担任Nuvation Bio公司首席财务官。在担任这一职务之前，Fox女士曾于2015年6月至2020年10月担任花旗集团董事总经理兼北美医疗保健企业和投资银行部门联席主管。2006年2月至2015年6月，Fox女士担任德意志银行董事总经理，最近还担任生命科学投资银行集团联席主管。在此之前，福克斯女士曾担任贝尔斯登医疗投资银行高级董事总经理、美国银行医疗投资银行副总裁、金融分析师、投资银行分析师、保诚矢量医疗集团和保诚证券公司医疗投资银行助理、副总裁。克斯女士在曼哈顿学院获得了金融和市场营销学士学位。
Jennifer Fox has served as Chief Biness Officer and Chief Financial Officer Since December 2023. Previoly, Ms. Fox served as Chief Financial Officer at Nuvation Bio, Inc. (NYSE: NUVB), an oncology foced biopharmaceutical company, from October 2020 until December 2023. Prior to this role, Ms. Fox served as Managing Director, Co Head of North America Healthcare Corporate and Investment Banking Group at Citigroup from June 2015 to October 2020. From February 2006 to June 2015, Ms. Fox served as Managing Director at Deutsche Bank, and most recently also as Co Head of Life Sciences Investment Banking Group. Prior to that, Ms. Fox served as Senior Managing Director Healthcare Investment Banking at Bear Stearns, Vice President Healthcare Investment Banking at Bank of America and Financial Analyst, Investment Banking Analyst, Associate, Vice President, Health Care Investment Banking at Prudential Vector Healthcare Group and Prudential Securities Incorporated. Ms. Fox serves on the board of directors for Apogee Therapeutics (Nasdaq: APGE), ProKidney Corp. (Nasdaq: PROK) and Life Science Cares. She has more than 25 years of experience in healthcare investment banking and has been a lead adviser to life science companies on over 125 financing and strategic transactions. Ms. Fox received B.S. degrees in Finance and Marketing from Manhattan College. - 詹妮弗·福克斯，自2022年7月以来一直在董事会和全科医生董事会任职。Fox女士自2020年10月起担任Nuvation Bio公司首席财务官。在担任这一职务之前，Fox女士曾于2015年6月至2020年10月担任花旗集团董事总经理兼北美医疗保健企业和投资银行部门联席主管。2006年2月至2015年6月，Fox女士担任德意志银行董事总经理，最近还担任生命科学投资银行集团联席主管。在此之前，福克斯女士曾担任贝尔斯登医疗投资银行高级董事总经理、美国银行医疗投资银行副总裁、金融分析师、投资银行分析师、保诚矢量医疗集团和保诚证券公司医疗投资银行助理、副总裁。克斯女士在曼哈顿学院获得了金融和市场营销学士学位。
- Jennifer Fox has served as Chief Biness Officer and Chief Financial Officer Since December 2023. Previoly, Ms. Fox served as Chief Financial Officer at Nuvation Bio, Inc. (NYSE: NUVB), an oncology foced biopharmaceutical company, from October 2020 until December 2023. Prior to this role, Ms. Fox served as Managing Director, Co Head of North America Healthcare Corporate and Investment Banking Group at Citigroup from June 2015 to October 2020. From February 2006 to June 2015, Ms. Fox served as Managing Director at Deutsche Bank, and most recently also as Co Head of Life Sciences Investment Banking Group. Prior to that, Ms. Fox served as Senior Managing Director Healthcare Investment Banking at Bear Stearns, Vice President Healthcare Investment Banking at Bank of America and Financial Analyst, Investment Banking Analyst, Associate, Vice President, Health Care Investment Banking at Prudential Vector Healthcare Group and Prudential Securities Incorporated. Ms. Fox serves on the board of directors for Apogee Therapeutics (Nasdaq: APGE), ProKidney Corp. (Nasdaq: PROK) and Life Science Cares. She has more than 25 years of experience in healthcare investment banking and has been a lead adviser to life science companies on over 125 financing and strategic transactions. Ms. Fox received B.S. degrees in Finance and Marketing from Manhattan College.
- Peter Harwin
-
Peter Harwin，自2023年6月起担任Apogee Therapeutics公司董事会成员，自2022年起担任Apogee Therapeutics公司董事会成员。Harwin先生是Fairmount Funds Management LLC的管理成员，这是一家医疗保健投资公司，他于2016年4月与他人共同创立。在加入Fairmount之前，Harwin先生是Boxer Capital，LLC投资团队的成员，Boxer Capital，LLC是一家投资基金，隶属于总部位于圣地亚哥的Tavistock Group。Harwin先生还担任Cogent Biosciences, Inc.（纳斯达克：COGT）董事会主席，Viridian Therapeutics, Inc.（纳斯达克：VRDN）、Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）和Paragon Therapeutics，Inc.董事。Harwin先生拥有埃默里大学学士学位。
暂无英文简介 - Peter Harwin，自2023年6月起担任Apogee Therapeutics公司董事会成员，自2022年起担任Apogee Therapeutics公司董事会成员。Harwin先生是Fairmount Funds Management LLC的管理成员，这是一家医疗保健投资公司，他于2016年4月与他人共同创立。在加入Fairmount之前，Harwin先生是Boxer Capital，LLC投资团队的成员，Boxer Capital，LLC是一家投资基金，隶属于总部位于圣地亚哥的Tavistock Group。Harwin先生还担任Cogent Biosciences, Inc.（纳斯达克：COGT）董事会主席，Viridian Therapeutics, Inc.（纳斯达克：VRDN）、Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）和Paragon Therapeutics，Inc.董事。Harwin先生拥有埃默里大学学士学位。
- 暂无英文简介
- Jennifer Fox
-
Jennifer Fox，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2023年5月起担任Apogee Therapeutics，LLC管理委员会成员。Fox女士自2020年10月起担任生物制药公司Nuvation Bio Inc.（纽约证券交易所代码：NUVB）的首席财务官。在加入Nuvation Bio之前，Fox女士曾于2015年6月至2020年10月在全球投资银行花旗集团（纽约证券交易所代码：C）担任董事总经理兼北美医疗保健企业和投资银行部门联席主管。2006年2月至2015年6月，福克斯女士担任全球投资银行德意志银行（纽约证券交易所代码：DB）董事总经理，最近担任生命科学投资银行集团联席主管。福克斯女士自2022年7月起担任生物技术公司ProKidney Corp.（纳斯达克：PROK）的董事会成员。福克斯在曼哈顿学院获得了金融和市场营销学士学位。
暂无英文简介 - Jennifer Fox，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2023年5月起担任Apogee Therapeutics，LLC管理委员会成员。Fox女士自2020年10月起担任生物制药公司Nuvation Bio Inc.（纽约证券交易所代码：NUVB）的首席财务官。在加入Nuvation Bio之前，Fox女士曾于2015年6月至2020年10月在全球投资银行花旗集团（纽约证券交易所代码：C）担任董事总经理兼北美医疗保健企业和投资银行部门联席主管。2006年2月至2015年6月，福克斯女士担任全球投资银行德意志银行（纽约证券交易所代码：DB）董事总经理，最近担任生命科学投资银行集团联席主管。福克斯女士自2022年7月起担任生物技术公司ProKidney Corp.（纳斯达克：PROK）的董事会成员。福克斯在曼哈顿学院获得了金融和市场营销学士学位。
- 暂无英文简介
- Andrew Gottesdiener
-
Andrew Gottesdiener自2024年11月起担任Korsana董事会成员。Gottesdiener博士是投资公司Venrock Healthcare Capital Partners在其纽约办事处的合伙人，在那里他专注于医疗保健投资。Gottesdiener博士还是Apogee Therapeutics，Inc.（纳斯达克：APGE）的联合创始人，该公司是一家临床阶段生物技术公司，自2022年以来一直担任Apogee的董事会成员。在2018年9月全职加入Venrock Healthcare Capital Partners之前，Gottesdiener博士获得了威尔康乃尔医学院的医学博士学位，在此期间，他获得了HHMI夏季基础科学研究奖学金。他还拥有哥伦比亚大学商学院的工商管理硕士学位。Gottesdiener博士在圣路易斯华盛顿大学获得经济学学士学位。
Andrew Gottesdiener has served as a member of the Korsana board of directors since November 2024. Dr. Gottesdiener is a partner at Venrock Healthcare Capital Partners, an investment firm, in its New York office, where he focuses on healthcare investments. Dr. Gottesdiener is also a co founder of Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical stage biotechnology company, and has served as a member of Apogee's board since 2022. Prior to joining Venrock Healthcare Capital Partners full time in September 2018, Dr. Gottesdiener earned his M.D. from Weill Cornell Medical College, during which time he received an HHMI summer fellowship for basic science research. He also has an M.B.A. from Columbia Business School. Dr. Gottesdiener received an A.B. in Economics from Washington University in St. Louis. - Andrew Gottesdiener自2024年11月起担任Korsana董事会成员。Gottesdiener博士是投资公司Venrock Healthcare Capital Partners在其纽约办事处的合伙人，在那里他专注于医疗保健投资。Gottesdiener博士还是Apogee Therapeutics，Inc.（纳斯达克：APGE）的联合创始人，该公司是一家临床阶段生物技术公司，自2022年以来一直担任Apogee的董事会成员。在2018年9月全职加入Venrock Healthcare Capital Partners之前，Gottesdiener博士获得了威尔康乃尔医学院的医学博士学位，在此期间，他获得了HHMI夏季基础科学研究奖学金。他还拥有哥伦比亚大学商学院的工商管理硕士学位。Gottesdiener博士在圣路易斯华盛顿大学获得经济学学士学位。
- Andrew Gottesdiener has served as a member of the Korsana board of directors since November 2024. Dr. Gottesdiener is a partner at Venrock Healthcare Capital Partners, an investment firm, in its New York office, where he focuses on healthcare investments. Dr. Gottesdiener is also a co founder of Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical stage biotechnology company, and has served as a member of Apogee's board since 2022. Prior to joining Venrock Healthcare Capital Partners full time in September 2018, Dr. Gottesdiener earned his M.D. from Weill Cornell Medical College, during which time he received an HHMI summer fellowship for basic science research. He also has an M.B.A. from Columbia Business School. Dr. Gottesdiener received an A.B. in Economics from Washington University in St. Louis.
- William Jones, Jr.
-
William Jones自2023年6月起担任Apogee Therapeutics公司董事会成员，自2023年5月起担任Apogee Therapeutics公司董事会成员。琼斯先生曾在生物制药公司、辉瑞公司（纽约证券交易所代码：PFE）的子公司Biohaven制药控股有限公司担任偏头痛和常见疾病首席商务官，在那里他负责建立公司的商业能力，并于2019年4月至2022年12月推出首个获得FDA批准的产品（Nurtec ODT）。在加入Biohaven制药公司之前，琼斯先生于2016年1月至2019年3月担任制药公司Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的副总裁兼销售和商业运营主管。琼斯先生自2022年8月起担任数字医药公司Akili, Inc.（纳斯达克：AKLI）的董事会成员。琼斯在美国空军学院获得了人为因素工程学士学位，在德克萨斯农工大学获得了工业工程硕士学位，在斯坦福大学商学院获得了工商管理硕士学位。
William Jones, Jr.,has served as a member of Apogee Therapeutics, Inc. Board since June 2023 and as a member of the board of managers of Apogee Therapeutics, LLC since May 2023. Mr. Jones previously served as Chief Commercial Officer, Migraine and Common Diseases of Biohaven Pharmaceuticals Holding Company Ltd., a biopharmaceutical company and subsidiary of Pfizer Inc. (NYSE: PFE), where he was responsible for building the company's commercial capability and launching its first FDA-approved product (Nurtec ODT), from April 2019 to December 2022. Prior to Biohaven Pharmaceuticals, Mr. Jones served as Vice President, Head of Sales and Commercial Operations for the general medicine business unit of Takeda Pharmaceutical Company Limited (NYSE: TAK), a pharmaceutical company, from January 2016 to March 2019. Mr. Jones has served on the board of directors of Akili, Inc. (Nasdaq: AKLI), a digital medicine company, since August 2022. Mr. Jones received his B.S. in human factors engineering from the U.S. Air Force Academy, M.S. in industrial engineering from Texas A&M University and M.B.A. from the Stanford University Graduate School of Business. - William Jones自2023年6月起担任Apogee Therapeutics公司董事会成员，自2023年5月起担任Apogee Therapeutics公司董事会成员。琼斯先生曾在生物制药公司、辉瑞公司（纽约证券交易所代码：PFE）的子公司Biohaven制药控股有限公司担任偏头痛和常见疾病首席商务官，在那里他负责建立公司的商业能力，并于2019年4月至2022年12月推出首个获得FDA批准的产品（Nurtec ODT）。在加入Biohaven制药公司之前，琼斯先生于2016年1月至2019年3月担任制药公司Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的副总裁兼销售和商业运营主管。琼斯先生自2022年8月起担任数字医药公司Akili, Inc.（纳斯达克：AKLI）的董事会成员。琼斯在美国空军学院获得了人为因素工程学士学位，在德克萨斯农工大学获得了工业工程硕士学位，在斯坦福大学商学院获得了工商管理硕士学位。
- William Jones, Jr.,has served as a member of Apogee Therapeutics, Inc. Board since June 2023 and as a member of the board of managers of Apogee Therapeutics, LLC since May 2023. Mr. Jones previously served as Chief Commercial Officer, Migraine and Common Diseases of Biohaven Pharmaceuticals Holding Company Ltd., a biopharmaceutical company and subsidiary of Pfizer Inc. (NYSE: PFE), where he was responsible for building the company's commercial capability and launching its first FDA-approved product (Nurtec ODT), from April 2019 to December 2022. Prior to Biohaven Pharmaceuticals, Mr. Jones served as Vice President, Head of Sales and Commercial Operations for the general medicine business unit of Takeda Pharmaceutical Company Limited (NYSE: TAK), a pharmaceutical company, from January 2016 to March 2019. Mr. Jones has served on the board of directors of Akili, Inc. (Nasdaq: AKLI), a digital medicine company, since August 2022. Mr. Jones received his B.S. in human factors engineering from the U.S. Air Force Academy, M.S. in industrial engineering from Texas A&M University and M.B.A. from the Stanford University Graduate School of Business.
- Tomas Kiselak
-
Tomas Kiselak，自2023年6月起担任Apogee Therapeutics公司董事会成员，自2022年起担任Apogee Therapeutics公司董事会成员。Kiselak先生是Fairmount Funds Management LLC的管理成员，这是他于2016年4月与他人共同创立的一家医疗保健投资公司。在加入Fairmount之前，Kiselak先生是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）董事会主席，并担任Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）和几家私营公司的董事。他在阿默斯特学院获得了神经科学和经济学学士位。
暂无英文简介 - Tomas Kiselak，自2023年6月起担任Apogee Therapeutics公司董事会成员，自2022年起担任Apogee Therapeutics公司董事会成员。Kiselak先生是Fairmount Funds Management LLC的管理成员，这是他于2016年4月与他人共同创立的一家医疗保健投资公司。在加入Fairmount之前，Kiselak先生是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）董事会主席，并担任Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）和几家私营公司的董事。他在阿默斯特学院获得了神经科学和经济学学士位。
- 暂无英文简介
- Nimish Shah
-
Nimish Shah自2024年11月起担任Korsana董事会成员。Shah先生是投资公司Venrock Healthcare Capital Partners的合伙人，在那里他专注于该公司的公开和交叉生物技术投资。Shah先生于2013年加入Venrock Healthcare Capital Partners，自2010年以来一直投资于公共和私营医疗保健公司。Shah先生还是Apogee Therapeutics，Inc.（纳斯达克：APGE）的联合创始人和董事会成员，该公司是一家临床阶段生物技术公司，自2022年以来一直在该公司任职。Shah先生此前曾担任Instil Bio, Inc.（纳斯达克：TIL）的董事至2021年12月，并担任LianBio（纳斯达克：LAN）、Biohaven Ltd.（NYSE：BHVN）、Viridian Therapeutics, Inc.，以及Dianthus Therapeutics，Inc.（纳斯达克：VRDN）的董事会观察员。Shah先生拥有罗格斯药学院的药学学士学位、哥伦比亚大学梅尔曼公共卫生学院的公共卫生硕士学位和哥伦比亚商学院的工商管理硕士学位。他是哥伦比亚商学院医疗保健和药品管理顾问委员会的成员。
Nimish Shah has served as a member of the Korsana board of directors since November 2024. Mr. Shah is a Partner at Venrock Healthcare Capital Partners, an investment firm, where he focuses on the firm's public and crossover biotech investments. Mr. Shah joined Venrock Healthcare Capital Partners in 2013 and has invested in public and private healthcare companies since 2010. Mr. Shah is also a co founder and a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical stage biotechnology company, where he has served since 2022. Mr. Shah previously served as a director for Instil Bio, Inc. (Nasdaq: TIL) until December 2021 and as a board observer for LianBio (Nasdaq: LIAN), Biohaven Ltd. (NYSE: BHVN), Viridian Therapeutics, Inc. (Nasdaq: VRDN), and Dianthus Therapeutics, Inc. (Nasdaq: DNTH). Mr. Shah holds a B.S. in Pharmacy from Rutgers College of Pharmacy, an M.P.H. from the Mailman School of Public Health at Columbia University, and an M.B.A. from Columbia Business School. He is a member of the Columbia Business School Healthcare and Pharmaceutical Management Advisory Board. - Nimish Shah自2024年11月起担任Korsana董事会成员。Shah先生是投资公司Venrock Healthcare Capital Partners的合伙人，在那里他专注于该公司的公开和交叉生物技术投资。Shah先生于2013年加入Venrock Healthcare Capital Partners，自2010年以来一直投资于公共和私营医疗保健公司。Shah先生还是Apogee Therapeutics，Inc.（纳斯达克：APGE）的联合创始人和董事会成员，该公司是一家临床阶段生物技术公司，自2022年以来一直在该公司任职。Shah先生此前曾担任Instil Bio, Inc.（纳斯达克：TIL）的董事至2021年12月，并担任LianBio（纳斯达克：LAN）、Biohaven Ltd.（NYSE：BHVN）、Viridian Therapeutics, Inc.，以及Dianthus Therapeutics，Inc.（纳斯达克：VRDN）的董事会观察员。Shah先生拥有罗格斯药学院的药学学士学位、哥伦比亚大学梅尔曼公共卫生学院的公共卫生硕士学位和哥伦比亚商学院的工商管理硕士学位。他是哥伦比亚商学院医疗保健和药品管理顾问委员会的成员。
- Nimish Shah has served as a member of the Korsana board of directors since November 2024. Mr. Shah is a Partner at Venrock Healthcare Capital Partners, an investment firm, where he focuses on the firm's public and crossover biotech investments. Mr. Shah joined Venrock Healthcare Capital Partners in 2013 and has invested in public and private healthcare companies since 2010. Mr. Shah is also a co founder and a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical stage biotechnology company, where he has served since 2022. Mr. Shah previously served as a director for Instil Bio, Inc. (Nasdaq: TIL) until December 2021 and as a board observer for LianBio (Nasdaq: LIAN), Biohaven Ltd. (NYSE: BHVN), Viridian Therapeutics, Inc. (Nasdaq: VRDN), and Dianthus Therapeutics, Inc. (Nasdaq: DNTH). Mr. Shah holds a B.S. in Pharmacy from Rutgers College of Pharmacy, an M.P.H. from the Mailman School of Public Health at Columbia University, and an M.B.A. from Columbia Business School. He is a member of the Columbia Business School Healthcare and Pharmaceutical Management Advisory Board.
- Michael Henderson
-
Michael Henderson，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC管理委员会成员，自2022年9月起担任Apogee Therapeutics，Inc.首席执行官。亨德森博士是一位经验丰富的生物技术高管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他领导了多家公司的创建，启动了大量的药物开发项目，并带领团队获得了两项FDA的批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月担任处于商业化阶段的生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，确定和投资新技术，并负责业务开发和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。亨德森博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。亨德森博士还曾担任BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，亨德森博士于2015年1月至2016年4月在全球管理咨询公司麦肯锡工作，在此之前，他于2011年8月与他人共同创立了生物技术公司PellePharm，Inc.。亨德森博士自2021年2月起担任专注于医疗保健行业的特殊目的收购公司ARYA科学并购公司IV（纳斯达克：ARYD）的董事会成员，自2023年6月起担任生物技术公司Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）的董事会成员。亨德森博士在哈佛大学获得了全球健康学士学位，在斯坦福大学获得了医学博士学位。
Michael Henderson,has served as a member of Apogee Therapeutics, Inc. Board since June 2023, as a member of the board of managers of Apogee Therapeutics, LLC since 2022 and as Apogee Therapeutics, Inc. Chief Executive Officer since September 2022. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co-founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021 and Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a biotechnology company, since June 2023. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University. - Michael Henderson，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC管理委员会成员，自2022年9月起担任Apogee Therapeutics，Inc.首席执行官。亨德森博士是一位经验丰富的生物技术高管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他领导了多家公司的创建，启动了大量的药物开发项目，并带领团队获得了两项FDA的批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月担任处于商业化阶段的生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，确定和投资新技术，并负责业务开发和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。亨德森博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。亨德森博士还曾担任BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，亨德森博士于2015年1月至2016年4月在全球管理咨询公司麦肯锡工作，在此之前，他于2011年8月与他人共同创立了生物技术公司PellePharm，Inc.。亨德森博士自2021年2月起担任专注于医疗保健行业的特殊目的收购公司ARYA科学并购公司IV（纳斯达克：ARYD）的董事会成员，自2023年6月起担任生物技术公司Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）的董事会成员。亨德森博士在哈佛大学获得了全球健康学士学位，在斯坦福大学获得了医学博士学位。
- Michael Henderson,has served as a member of Apogee Therapeutics, Inc. Board since June 2023, as a member of the board of managers of Apogee Therapeutics, LLC since 2022 and as Apogee Therapeutics, Inc. Chief Executive Officer since September 2022. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co-founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021 and Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a biotechnology company, since June 2023. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.
高管简历
中英对照 | 中文 | 英文- Michael Henderson
Michael Henderson，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC管理委员会成员，自2022年9月起担任Apogee Therapeutics，Inc.首席执行官。亨德森博士是一位经验丰富的生物技术高管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他领导了多家公司的创建，启动了大量的药物开发项目，并带领团队获得了两项FDA的批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月担任处于商业化阶段的生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，确定和投资新技术，并负责业务开发和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。亨德森博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。亨德森博士还曾担任BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，亨德森博士于2015年1月至2016年4月在全球管理咨询公司麦肯锡工作，在此之前，他于2011年8月与他人共同创立了生物技术公司PellePharm，Inc.。亨德森博士自2021年2月起担任专注于医疗保健行业的特殊目的收购公司ARYA科学并购公司IV（纳斯达克：ARYD）的董事会成员，自2023年6月起担任生物技术公司Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）的董事会成员。亨德森博士在哈佛大学获得了全球健康学士学位，在斯坦福大学获得了医学博士学位。
Michael Henderson,has served as a member of Apogee Therapeutics, Inc. Board since June 2023, as a member of the board of managers of Apogee Therapeutics, LLC since 2022 and as Apogee Therapeutics, Inc. Chief Executive Officer since September 2022. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co-founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021 and Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a biotechnology company, since June 2023. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.- Michael Henderson，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC管理委员会成员，自2022年9月起担任Apogee Therapeutics，Inc.首席执行官。亨德森博士是一位经验丰富的生物技术高管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他领导了多家公司的创建，启动了大量的药物开发项目，并带领团队获得了两项FDA的批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月担任处于商业化阶段的生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，确定和投资新技术，并负责业务开发和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。亨德森博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。亨德森博士还曾担任BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，亨德森博士于2015年1月至2016年4月在全球管理咨询公司麦肯锡工作，在此之前，他于2011年8月与他人共同创立了生物技术公司PellePharm，Inc.。亨德森博士自2021年2月起担任专注于医疗保健行业的特殊目的收购公司ARYA科学并购公司IV（纳斯达克：ARYD）的董事会成员，自2023年6月起担任生物技术公司Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）的董事会成员。亨德森博士在哈佛大学获得了全球健康学士学位，在斯坦福大学获得了医学博士学位。
- Michael Henderson,has served as a member of Apogee Therapeutics, Inc. Board since June 2023, as a member of the board of managers of Apogee Therapeutics, LLC since 2022 and as Apogee Therapeutics, Inc. Chief Executive Officer since September 2022. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co-founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021 and Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a biotechnology company, since June 2023. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.
- Carl Dambkowski
Carl Dambkowski，自2022年9月起担任Apogee Therapeutics，Inc.首席医疗官。在加入Apogee之前，Dambkowski博士曾担任多家公司的战略和临床领导，包括2021年7月至2022年9月担任私营生物技术公司QED治疗公司的首席医疗官；2018年3月至2021年6月担任私营生物生态公司Origin Biosciences公司的首席战略官和运营执行副总裁；2020年1月至2022年9月担任私营生物技术公司Navire Pharma公司的首席医疗官，根据初步临床数据，他担任临床主任，在IND之前开始对BBP-398进行临床试验，并通过初步概念验证数据将该化合物授权给百时美施贵宝，用于治疗软骨发育不全的低剂量infigratinib。他是使TRUSELTIQ （infigratinib）和NULIBRY （fosdenopterin）分别在QED疗法和Origin Biosciences通过监管审查和FDA批准的核心团队的一员。从2016年7月到2018年3月，丹布科夫斯基博士在全球管理咨询公司麦肯锡担任助理，在那里他为世界各地的生物技术和制药公司提供一系列研发活动的建议。2015年1月，丹布科夫斯基博士与人共同创立了Novonate，Inc.，这是一家专注于为新生儿制造救生设备的私营医疗设备公司。Dambkowski博士与人合著了许多同行评议的出版物和科学摘要，并且是多项已发表和已获授权专利的指定发明人。达姆布科夫斯基博士曾在斯坦福大学接受医师培训，并在那里获得了生物工程专业的医学博士学位。他还拥有哥伦比亚大学的硕士学位和斯坦福大学的（荣誉）学士学位。
Carl Dambkowski,has served as Apogee Therapeutics, Inc. Chief Medical Officer since September 2022. Prior to joining Apogee, Dr. Dambkowski served as a strategic and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from July 2021 to September 2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from March 2018 to June 2021; Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from January 2020 to September 2022, where he served as the clinical lead starting prior to IND for BBP-398 through the out licensing of the compound to Bristol-Myers Squibb based on initial clinical data and for low-dose infigratinib in achondroplasia through initial proof-of-concept data. He was part of the core team that brought TRUSELTIQ (infigratinib) and NULIBRY (fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From July 2016 to March 2018, Dr. Dambkowski was an associate at McKinsey & Company, a global management consulting firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr. Dambkowski co-founded Novonate, Inc., a private medical device company focused on building life-saving devices for neonates, in January 2015. Dr. Dambkowski has coauthored numerous peer-reviewed publications and scientific abstracts and is a named inventor on multiple published and granted patents. Dr. Dambkowski was trained as a physician at Stanford University, where he also received his M.D. with a concentration in bioengineering. He also holds an M.A. from Columbia University and a B.A. (with honors) from Stanford University.- Carl Dambkowski，自2022年9月起担任Apogee Therapeutics，Inc.首席医疗官。在加入Apogee之前，Dambkowski博士曾担任多家公司的战略和临床领导，包括2021年7月至2022年9月担任私营生物技术公司QED治疗公司的首席医疗官；2018年3月至2021年6月担任私营生物生态公司Origin Biosciences公司的首席战略官和运营执行副总裁；2020年1月至2022年9月担任私营生物技术公司Navire Pharma公司的首席医疗官，根据初步临床数据，他担任临床主任，在IND之前开始对BBP-398进行临床试验，并通过初步概念验证数据将该化合物授权给百时美施贵宝，用于治疗软骨发育不全的低剂量infigratinib。他是使TRUSELTIQ （infigratinib）和NULIBRY （fosdenopterin）分别在QED疗法和Origin Biosciences通过监管审查和FDA批准的核心团队的一员。从2016年7月到2018年3月，丹布科夫斯基博士在全球管理咨询公司麦肯锡担任助理，在那里他为世界各地的生物技术和制药公司提供一系列研发活动的建议。2015年1月，丹布科夫斯基博士与人共同创立了Novonate，Inc.，这是一家专注于为新生儿制造救生设备的私营医疗设备公司。Dambkowski博士与人合著了许多同行评议的出版物和科学摘要，并且是多项已发表和已获授权专利的指定发明人。达姆布科夫斯基博士曾在斯坦福大学接受医师培训，并在那里获得了生物工程专业的医学博士学位。他还拥有哥伦比亚大学的硕士学位和斯坦福大学的（荣誉）学士学位。
- Carl Dambkowski,has served as Apogee Therapeutics, Inc. Chief Medical Officer since September 2022. Prior to joining Apogee, Dr. Dambkowski served as a strategic and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from July 2021 to September 2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from March 2018 to June 2021; Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from January 2020 to September 2022, where he served as the clinical lead starting prior to IND for BBP-398 through the out licensing of the compound to Bristol-Myers Squibb based on initial clinical data and for low-dose infigratinib in achondroplasia through initial proof-of-concept data. He was part of the core team that brought TRUSELTIQ (infigratinib) and NULIBRY (fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From July 2016 to March 2018, Dr. Dambkowski was an associate at McKinsey & Company, a global management consulting firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr. Dambkowski co-founded Novonate, Inc., a private medical device company focused on building life-saving devices for neonates, in January 2015. Dr. Dambkowski has coauthored numerous peer-reviewed publications and scientific abstracts and is a named inventor on multiple published and granted patents. Dr. Dambkowski was trained as a physician at Stanford University, where he also received his M.D. with a concentration in bioengineering. He also holds an M.A. from Columbia University and a B.A. (with honors) from Stanford University.
- Jane Pritchett Henderson
Jane Pritchett Henderson，自2023年1月起担任Apogee Therapeutics公司首席财务官。在加入Apogee之前，Henderson女士于2020年12月至2022年11月担任Adagio Therapeutics, Inc.（现为Invivyd，Inc.）（纳斯达克：IVVD）的首席财务官和首席商务官。Adagio Therapeutics，Inc.是一家为冠状病毒开发抗体疗法的生物技术公司。在加入Adagio Therapeutics之前，亨德森女士于2018年6月至2020年12月担任私营病毒免疫肿瘤公司Turnstone Biologics Corp.的首席财务官,2017年1月至2018年6月担任基因治疗公司Voyager Therapeutics, Inc.（纳斯达克：VYGR）的首席财务官和企业发展高级副总裁，并于2013年2月至2016年11月担任私营肿瘤生物制药公司Kolltan制药公司的高级副总裁、首席财务和业务官，Kolltan制药被Kolltan制药收购之前，在医疗保健投资银行工作了近20年后，亨德森在生物制药公司担任过各种财务和业务发展主管职务。在过去五年中，亨德森女士自2019年4月起担任生物技术公司Akero Therapeutics, Inc.（纳斯达克：AKRO）的董事会成员，自2018年1月起担任生物制药公司IVERIC Bio，Inc.（纳斯达克：ISEE）的董事会成员，以及私营生物制药公司Ventus Therapeutics，Inc.的董事会成员。2018年10月至2021年11月，她还担任生物制药公司Sesen Bio公司（纳斯达克：SESN）的董事会成员。亨德森女士还在南方卫理公会大学戴德曼学院执行委员会任职。亨德森在杜克大学获得了心理学学士学位。
Jane Pritchett Henderson,has served as Apogee Therapeutics, Inc. Chief Financial Officer since January 2023. Prior to joining Apogee, Ms. Henderson served as the Chief Financial Officer and Chief Business Officer of Adagio Therapeutics, Inc. (now Invivyd, Inc.) (Nasdaq: IVVD), a biotechnology company developing antibody therapeutics for coronaviruses, from December 2020 to November 2022. Prior to joining Adagio Therapeutics, Ms. Henderson served as Chief Financial Officer of Turnstone Biologics Corp., a private viral immuno-oncology company, from June 2018 to December 2020, as Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company, from January 2017 to June 2018, and as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., a private oncology biopharmaceutical company, from February 2013 until November 2016, when Kolltan Pharmaceuticals was acquired by Celldex Therapeutics, Inc. Prior to Kolltan Pharmaceuticals, Ms. Henderson served in various financial and business development executive roles at biopharmaceutical companies after spending almost 20 years in health care investment banking. During the past five years, Ms. Henderson has served on the board of directors of Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, since April 2019, IVERIC Bio, Inc. (Nasdaq: ISEE), a biopharmaceutical company, since January 2018, and Ventus Therapeutics, Inc., a private biopharmaceutical company. She also served on the board of directors of Sesen Bio Inc. (Nasdaq: SESN), a biopharmaceutical company, from October 2018 to November 2021. Ms. Henderson also serves on the Dedman College Executive Board of Southern Methodist University. Ms. Henderson received a B.S. in psychology from Duke University.- Jane Pritchett Henderson，自2023年1月起担任Apogee Therapeutics公司首席财务官。在加入Apogee之前，Henderson女士于2020年12月至2022年11月担任Adagio Therapeutics, Inc.（现为Invivyd，Inc.）（纳斯达克：IVVD）的首席财务官和首席商务官。Adagio Therapeutics，Inc.是一家为冠状病毒开发抗体疗法的生物技术公司。在加入Adagio Therapeutics之前，亨德森女士于2018年6月至2020年12月担任私营病毒免疫肿瘤公司Turnstone Biologics Corp.的首席财务官,2017年1月至2018年6月担任基因治疗公司Voyager Therapeutics, Inc.（纳斯达克：VYGR）的首席财务官和企业发展高级副总裁，并于2013年2月至2016年11月担任私营肿瘤生物制药公司Kolltan制药公司的高级副总裁、首席财务和业务官，Kolltan制药被Kolltan制药收购之前，在医疗保健投资银行工作了近20年后，亨德森在生物制药公司担任过各种财务和业务发展主管职务。在过去五年中，亨德森女士自2019年4月起担任生物技术公司Akero Therapeutics, Inc.（纳斯达克：AKRO）的董事会成员，自2018年1月起担任生物制药公司IVERIC Bio，Inc.（纳斯达克：ISEE）的董事会成员，以及私营生物制药公司Ventus Therapeutics，Inc.的董事会成员。2018年10月至2021年11月，她还担任生物制药公司Sesen Bio公司（纳斯达克：SESN）的董事会成员。亨德森女士还在南方卫理公会大学戴德曼学院执行委员会任职。亨德森在杜克大学获得了心理学学士学位。
- Jane Pritchett Henderson,has served as Apogee Therapeutics, Inc. Chief Financial Officer since January 2023. Prior to joining Apogee, Ms. Henderson served as the Chief Financial Officer and Chief Business Officer of Adagio Therapeutics, Inc. (now Invivyd, Inc.) (Nasdaq: IVVD), a biotechnology company developing antibody therapeutics for coronaviruses, from December 2020 to November 2022. Prior to joining Adagio Therapeutics, Ms. Henderson served as Chief Financial Officer of Turnstone Biologics Corp., a private viral immuno-oncology company, from June 2018 to December 2020, as Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company, from January 2017 to June 2018, and as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., a private oncology biopharmaceutical company, from February 2013 until November 2016, when Kolltan Pharmaceuticals was acquired by Celldex Therapeutics, Inc. Prior to Kolltan Pharmaceuticals, Ms. Henderson served in various financial and business development executive roles at biopharmaceutical companies after spending almost 20 years in health care investment banking. During the past five years, Ms. Henderson has served on the board of directors of Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, since April 2019, IVERIC Bio, Inc. (Nasdaq: ISEE), a biopharmaceutical company, since January 2018, and Ventus Therapeutics, Inc., a private biopharmaceutical company. She also served on the board of directors of Sesen Bio Inc. (Nasdaq: SESN), a biopharmaceutical company, from October 2018 to November 2021. Ms. Henderson also serves on the Dedman College Executive Board of Southern Methodist University. Ms. Henderson received a B.S. in psychology from Duke University.
- Rebecca Dabora
Rebecca Dabora，自2023年5月起担任Apogee Therapeutics，Inc.首席技术官。在加入Apogee之前，Dabora博士于2020年7月至2023年6月担任Adagio Therapeutics, Inc.（现为Invivyd，Inc.）（纳斯达克：IVVD）的首席技术和制造官，该公司是一家为冠状病毒开发抗体疗法的生物技术公司。在加入Adagio Therapeutics之前，Dabora博士于2019年7月至2020年7月担任私有基因治疗公司SwanBio Therapeutics的临时首席技术官。在加入SwanBio Therapeutics之前，Dabora博士于2016年3月至2017年3月担任私营生物技术公司Aspyrian Therapeutics，Inc.（现为乐天医疗）的首席技术官。自2005年7月以来，Dabora博士还担任RDBio Consulting LLC的总裁兼负责人。RDBio Consulting LLC是一家咨询公司，为生物制药公司提供临床和商业阶段产品以及风险投资公司的咨询服务，专注于技术运营和CMC相关主题，包括合同制造评估和管理、工艺验证、工艺开发、CMC监管备案准备、战略和组织发展以及项目管理。在加入RDBio Consulting之前，Dabora博士曾在Altus Pharmaceuticals、渤健公司和默沙东公司任职。Dabora博士在麻省理工学院获得应用生物科学和生化工程博士学位，在鲍登学院获得生物化学学士学位。
Rebecca Dabora,has served as Apogee Therapeutics, Inc. Chief Technical Officer since May 2023. Prior to joining Apogee, Dr. Dabora served as Chief Technology and Manufacturing Officer of Adagio Therapeutics, Inc. (now Invivyd, Inc.) (Nasdaq: IVVD), a biotechnology company developing antibody therapeutics for coronaviruses, from July 2020 to June 2023. Prior to joining Adagio Therapeutics, Dr. Dabora served as Interim Chief Technology Officer of SwanBio Therapeutics, a private gene therapy company, from July 2019 to July 2020. Prior to joining SwanBio Therapeutics, Dr. Dabora served as Chief Technology Officer of Aspyrian Therapeutics, Inc. (now Rakuten Medical), a private biotechnology company, from March 2016 to March 2017. Dr. Dabora has also served as President and Principal of RDBio Consulting LLC, a consulting company that advises biopharmaceutical companies with clinical and commercial phase products and venture capital firms and that is focused on technical operations and CMC-related topics, including contract manufacturing assessment and management, process validation, process development, CMC regulatory filing preparation, strategic and organizational development and program management, since July 2005. Prior to RDBio Consulting, Dr. Dabora held positions at Altus Pharmaceuticals, Biogen Inc. and Merck & Co. Dr. Dabora received a Ph.D. in applied biological sciences and biochemical engineering from Massachusetts Institute of Technology and a B.A. in biochemistry from Bowdoin College.- Rebecca Dabora，自2023年5月起担任Apogee Therapeutics，Inc.首席技术官。在加入Apogee之前，Dabora博士于2020年7月至2023年6月担任Adagio Therapeutics, Inc.（现为Invivyd，Inc.）（纳斯达克：IVVD）的首席技术和制造官，该公司是一家为冠状病毒开发抗体疗法的生物技术公司。在加入Adagio Therapeutics之前，Dabora博士于2019年7月至2020年7月担任私有基因治疗公司SwanBio Therapeutics的临时首席技术官。在加入SwanBio Therapeutics之前，Dabora博士于2016年3月至2017年3月担任私营生物技术公司Aspyrian Therapeutics，Inc.（现为乐天医疗）的首席技术官。自2005年7月以来，Dabora博士还担任RDBio Consulting LLC的总裁兼负责人。RDBio Consulting LLC是一家咨询公司，为生物制药公司提供临床和商业阶段产品以及风险投资公司的咨询服务，专注于技术运营和CMC相关主题，包括合同制造评估和管理、工艺验证、工艺开发、CMC监管备案准备、战略和组织发展以及项目管理。在加入RDBio Consulting之前，Dabora博士曾在Altus Pharmaceuticals、渤健公司和默沙东公司任职。Dabora博士在麻省理工学院获得应用生物科学和生化工程博士学位，在鲍登学院获得生物化学学士学位。
- Rebecca Dabora,has served as Apogee Therapeutics, Inc. Chief Technical Officer since May 2023. Prior to joining Apogee, Dr. Dabora served as Chief Technology and Manufacturing Officer of Adagio Therapeutics, Inc. (now Invivyd, Inc.) (Nasdaq: IVVD), a biotechnology company developing antibody therapeutics for coronaviruses, from July 2020 to June 2023. Prior to joining Adagio Therapeutics, Dr. Dabora served as Interim Chief Technology Officer of SwanBio Therapeutics, a private gene therapy company, from July 2019 to July 2020. Prior to joining SwanBio Therapeutics, Dr. Dabora served as Chief Technology Officer of Aspyrian Therapeutics, Inc. (now Rakuten Medical), a private biotechnology company, from March 2016 to March 2017. Dr. Dabora has also served as President and Principal of RDBio Consulting LLC, a consulting company that advises biopharmaceutical companies with clinical and commercial phase products and venture capital firms and that is focused on technical operations and CMC-related topics, including contract manufacturing assessment and management, process validation, process development, CMC regulatory filing preparation, strategic and organizational development and program management, since July 2005. Prior to RDBio Consulting, Dr. Dabora held positions at Altus Pharmaceuticals, Biogen Inc. and Merck & Co. Dr. Dabora received a Ph.D. in applied biological sciences and biochemical engineering from Massachusetts Institute of Technology and a B.A. in biochemistry from Bowdoin College.